Source: European Biotechnology

NeRRe Therapeutics: NeRRe Therapeutics pushes leads by 26m Series B financing

Read full article »

NeRRe Therapeutics's Competitors | NeRRe Therapeutics's News | NeRRe Therapeutics's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

CEO

Mary Kerr

CEO Approval Rating

73/100

Nerre is an England-based clinical-stage pharmaceutical company that researches and develops neurokinin receptor antagonist drugs to treat cough hypersensitivity disorders.